International Congress Amsterdam 2015


Tuberculosis: short-course chemotherapy

Year in review
Chairs: Jan-Willem Alfenaar (Groningen, Netherlands), Graham H. Bothamley (London, United Kingdom)
Aims: To present the evidence base for improving tuberculosis treatment with current and new drugs, discuss the evidence that suggests a need for shorter-course treatments for tuberculosis, the possible reasons for the problems that may be faced in shortening tuberculosis treatment with reference to the basic science of tuberculosis and present recommendations for future trials.
Target audience: Clinicians, clinical trialists, drug development organisations, public health officials, global tuberculosis funders, and basic scientists.
High-dose rifampicin and rifapentine in tuberculosis treatment
Amina Jindani (London, United Kingdom)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Four-month regimens: are they feasible?
Christian Lienhardt (Marseille, France)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Short-course treatment for multidrug-resistant tuberculosis: STREAM trials
Sarah Meredith (London, United Kingdom)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files